Replies to post #69031 on Amarin Corp Plc (AMRN)

[caddiedad]

Garbage in garbage out

[acuzuss]

i thought you just steered our conversation to pre Reduce-IT offer with CVRs? 1A is absolutely a must in determining BO price pre Reduce-IT. The suitor needs to know what information they're able to communicate when marketing/selling the drug.

[ladavis23]

Of course, I will be ridiculed, but I know for certain that JZ & Co burned many bridges in 2012 and into 2013. I was working for one of the lead book running managers for the AMRN offering in July 2013. Ajax has greater WS ties than me and he can also comment on that.

The AMRN story shifted during that time from a company with an incredibly special BB drug, to a company run by a management team that proved to be incompetent, in denial, and incredibly questionable. Of course, the only reason this still matter is that all of the major AMRN players are still with the company.

AMRN management lost much trust within the WS community and left many BP very reluctant to continue discussions that were taking place. This was based upon the fact that AMRN management was packaging the company like it was a Ferrari, and it turned out to really be a Pinto. Make no mistake, if any of the BP executives during that time pulled the trigger and bought out AMRN at $20+ as JZ was shopping, considering what took place, they would have been fired and probably out of the industry.

The feeling was that AMRN got side swiped big time by the FDA, (which I believe 100%) BUT the company was in no way shape or form prepared for it. AND that is the fault of AMRN. Again, none of this would matter except for the fact that all major AMRN players are still running the company. If there was a new team put in place, they would all have been running with a clean slate.

So the question is this, can BP be blamed for not wanting to have anything to do with this management NOW? I would suspect that BP is waiting for this AMRN team to blow it once again, and then come along and pick up pieces of the asset at pennies on the dollar. The drug remains intact, the science stays the same, only the equity in the company stock gets destroyed. Only the shareholders suffer. The integrity of the drug remains, it will still get in the hands of patients, and BP doesn't get fooled again. Of course, this only matters because the same players are making the same risk management mistakes are running AMRN that did in 2012-2013.